Galectin Therapeutics Inc.
GALTNASDAQHealthcare● Active
$2.40
+$0.07(+2.79%)
Market Cap$157727271
P/E Ratio—
52W High$7.13
52W Low$1.27
Galectin Therapeutics Inc. (GALT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GALT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.08
Est. -$0.06 · -33.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS
GALT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.09 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.06 | -$0.08 | -33.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.10 | -$0.08 | +20.0% | — | $0.04B | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.11 | -$0.13 | -18.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.16 | -$0.12 | +25.0% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.20 | -$0.15 | +25.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.16 | -$0.19 | -18.8% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.20 | -$0.18 | +10.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
—
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.10
EPS Surpr.
+20.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.11
EPS Surpr.
-18.2%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.16
EPS Surpr.
+25.0%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.20
EPS Surpr.
+25.0%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.16
EPS Surpr.
-18.8%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.20
EPS Surpr.
+10.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q2 FY2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q1 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2025 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2025 | $-0.11 | $-0.11 | $-0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -33.3% | $2.35 | $2.17 | -7.66% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +20.0% | $2.57 | $2.79 | +8.56% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -18.2% | $5.53 | $5.51 | -0.36% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +25.0% | $3.67 | $3.76 | +2.45% |
| ▲ Q2 FY2025 | May 15, 2025 | +25.0% | $1.30 | $1.32 | +1.54% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -18.8% | $1.52 | $1.22 | -19.74% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +10.0% | $2.90 | $2.75 | -5.17% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -25.0% | $2.11 | $2.25 | +6.64% |
Q2 FY2026-7.66%
Report Date
May 15, 2026
EPS Beat/Miss
-33.3%
Price Before
$2.35
Price After
$2.17
Q1 FY2026+8.56%
Report Date
Mar 31, 2026
EPS Beat/Miss
+20.0%
Price Before
$2.57
Price After
$2.79
Q4 FY2025-0.36%
Report Date
Nov 14, 2025
EPS Beat/Miss
-18.2%
Price Before
$5.53
Price After
$5.51
Q3 FY2025+2.45%
Report Date
Aug 14, 2025
EPS Beat/Miss
+25.0%
Price Before
$3.67
Price After
$3.76
Q2 FY2025+1.54%
Report Date
May 15, 2025
EPS Beat/Miss
+25.0%
Price Before
$1.30
Price After
$1.32
Q1 FY2025-19.74%
Report Date
Mar 31, 2025
EPS Beat/Miss
-18.8%
Price Before
$1.52
Price After
$1.22
Q4 FY2024-5.17%
Report Date
Nov 14, 2024
EPS Beat/Miss
+10.0%
Price Before
$2.90
Price After
$2.75
Q3 FY2024+6.64%
Report Date
Aug 13, 2024
EPS Beat/Miss
-25.0%
Price Before
$2.11
Price After
$2.25
Avg Beat Reaction+1.85%
Avg Miss Reaction-5.28%
Beat Rate4 / 8 quarters
Largest Move-19.74% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GALT ends December
Galectin Therapeutics Inc. (GALT) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.08 — missing the analyst consensus of $-0.06 by -33.3%. The next GALT earnings date is expected around September 1, 2026.
Each quarter, investors track GALT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GALT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GALT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GALT earnings · 5 questionsGalectin Therapeutics Inc.'s next earnings report is expected around September 1, 2026. GALT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GALT historically reports after market close (AMC).
GALT earnings datewhen is GALT earningsGALT next earnings datewhen does GALT report earningsGALT earnings calendar
▸ Source: FMP · Galectin Therapeutics Inc. SEC filings · US GAAP · Galectin Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026